Review article: Induction therapy for patients with active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 1, 2006, Pages 10-16

  Travis, S P L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; MESALAZINE; PLACEBO; SPD 476; STEROID;

CLINICAL STUDY; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; PANCREATITIS; PRIORITY JOURNAL; PROCTITIS; REMISSION; REVIEW; SYMPTOMATOLOGY; THERAPY EFFECT; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MESALAMINE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747607476     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03070.x     Document Type: Review

References (14)

1. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl. 5): V1-16.
2. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
3. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97.
4. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; 3: CD000543.
5. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004; 20: 143-9.
6. Irvine EJ. Assessing outcomes in clinical trials. In: Satsangi J, Sutherland L, eds. Inflammatory Bowel Diseases. London: Churchill Livingstone, 2003: 319-33.
7. Travis SPL, Hanauer SB, Richter J. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2005; 7: 475-84.
8. Hanauer SB, Sandborn WJ, Archambault A, Dallaire C, Yacyshyn B, Regalli G. Efficacy and safety of Asacol 4.8 g/day (800 mg tablet) compared with 2.4 g/day (400 mg tablet) in treating moderately active ulcerative colitis. Can J Gastroenterol 2006; 20 (Suppl. A): A 148.
9. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85.
10. Lichtenstein G, Kamm M, Sandborn W, Boddu P, Gubergrits N. SPD476, a novel once-daily, high dose mesalazine formulation is well tolerated and effective for the induction of remission of mild-to moderate ulcerative colitis: a Phase III study [abstract]. Gut 2005; 54 (Suppl. VII): A82.
11. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5.
12. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
13. Katz S, Kane S, Higgins P, Yacyshyn B, Eusebio R. Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores [DDW abstract]. Gastroenterology 2006; 130 (suppl. 2): A1-911. (Abstract).
14. Baron JH, Connell AM, Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964; 5375: 89-92.